A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

Cong, Jing; Zhang, Yuguang; Xue, Yadong; Zhang, Chuantao; Xu, Ming; Liu, Dong; Zhang, Ruiyan; Zhu, Hua

doi:10.3389/fmicb.2020.583525

Cited by 6 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, our results revealed distinctive changes in the microbiota composition after treatment compared with the findings before treatment using fecal samples. The EGFR-TKI, osimertinib, did not significantly change the relative abundance of gastrointestinal microbiota in a previous study [ 34 ], in line with our findings in the EGFR -mutant cohort. This result is probably attributable to the lack of a direct cytotoxic effect of EGFR-TKIs on the gastrointestinal even though one of their common AEs is diarrhea.…”

Section: Discussionsupporting

confidence: 92%

“…Previous research revealed no significant reduction in the alpha diversity of the gastrointestinal in patients with lung cancer compared to healthy individuals. However, they did not show the difference between EGFR -WT and EGFR -mutant cancer, as shown in our study [ 34 , 36 ]. This result is important for explaining the differences in biology between these lung cancer types.…”

Section: Discussioncontrasting

confidence: 50%

See 1 more Smart Citation

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Introduction Difference in clinical responses to cancer therapy in each patient is from several factors. Gastrointestinal microbiota is one of the reasons. However, this correlation remains unknown. This study aims to explore correlation between gastrointestinal microbiota profile and clinical outcomes in Thai advanced non-small cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) status. Methods We enrolled 13 patients with advanced EGFR–wild-type (WT) NSCLC who received chemotherapy and 15 patients with EGFR-mutant NSCLC who received EGFR tyrosine kinase inhibitors. We collected fecal samples at baseline and first disease evaluation and performed 16S rRNA gene sequencing by NGS to assess microbiota profile. The correlations between gastrointestinal microbiota and clinical variables were studied. Results The clinical characteristics were balanced between the cohorts, excluding significantly higher albumin levels in the EGFR-mutant group. Albumin was the only significant clinical factor affecting the treatment response in multivariate analysis (ORR 15.6%, P = 0.03). Proteobacteria counts were higher in the EGFR-WT group, whereas Bacteroidetes and Firmicutes counts were higher in the EGFR-mutant group. The alpha diversity of the gastrointestinal microbiome was significantly higher in the EGFR-mutant group (Shannon index: 3.82 vs. 3.25, P = 0.022). Following treatment, Proteobacteria counts were lower and Bacteroidetes and Firmicutes counts were higher in both cohorts; the changes were more prominent in the EGFR-WT cohort. No significant correlation between microbiota profile and treatment response were demonstrated in our study. However, beta diversity was significantly different according to severity of adverse events. Enrichment of Clostridia and Bacteroidia was associated with higher adverse event risk in the EGFR-WT cohort. Conclusions Proteobacteria was dominant in Thai lung cancer patients both EGFR-WT and EGFR-mutant, and this phylum maybe associate with lung cancer carcinogenesis. Chemotherapy altered the gastrointestinal microbiota, whereas EGFR-TKIs had less effects. Our findings highlight the potential predictive utility of the gastrointestinal microbiota for lung cancer carcinogenesis. Studies with larger cohorts and comparison with the healthy Thai population are ongoing to validate this pilot study.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussioncontrasting

confidence: 50%

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[7] This carcinogenic influence has been extensively explored in preclinical and clinical studies especially gastrointestinal and respiratory tract tumors. [8][9][10][11] Changes in gut and vaginal microbiome composition have been associated with virtually all gynecological cancers (e.g., ovarian, uterine, cervical, vaginal, and vulvar cancers, etc). [12,13] A burgeoning body of research suggests that individual microbiota differences might correlate with varying disease susceptibility.…”

Section: Introductionmentioning

confidence: 99%

Associations between gut microbiota and gynecological cancers: A bi-directional two-sample Mendelian randomization study

Kong,

Liu,

Wang

et al. 2024

Medicine

View full text Add to dashboard Cite

Growing evidence has suggested that gut microbiota is associated with gynecologic cancers. However, whether there is a causal relationship between these associations remains to be determined. A two-sample Mendelian randomization (MR) evaluation was carried out to investigate the mechanism associating gut microbiota and 3 prevalent gynecological cancers, ovarian cancer (OC), endometrial cancer, and cervical cancer as well as their subtypes in individuals of European ancestry. The Genome-wide association studies statistics, which are publically accessible, were used. Eligible instrumental single nucleotide polymorphisms that were significantly related to the gut microbiota were selected. Multiple MR analysis approaches were carried out, including inverse variance weighted, MR-Egger, Weighted Median methods, and a range of sensitivity analyses. Lastly, we undertook a reverse MR analysis to evaluate the potential of reverse causality. We sifted through 196 bacterial taxa and identified 33 suggestive causal relationships between genetic liability in the gut microbiota and gynecological cancers. We found that 11 of these genera could be pathogenic risk factors for gynecological cancers, while 19 could lessen the risk of cancer. In the other direction, gynecological cancers altered gut microbiota composition. Our MR analysis revealed that the gut microbiota was causally associated with OC, endometrial cancer, and cervical cancer. This may assist in providing new insights for further mechanistic and clinical studies of microbiota-mediated gynecological cancer.

show abstract

Effects of compound prebiotics as prophylactic and therapeutic supplementation in a mouse model of acute colitis

Cong

Wang²,

Gai

et al. 2023

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy

Cited by 6 publications

References 51 publications

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

Associations between gut microbiota and gynecological cancers: A bi-directional two-sample Mendelian randomization study

Effects of compound prebiotics as prophylactic and therapeutic supplementation in a mouse model of acute colitis

Contact Info

Product

Resources

About